Cell Source Beta vs. EBITDA
| CLCS Stock | USD 0.50 0.02 4.17% |
For Cell Source profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cell Source to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cell Source utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cell Source's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cell Source over time as well as its relative position and ranking within its peers.
Cell |
Cell Source EBITDA vs. Beta Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cell Source's current stock value. Our valuation model uses many indicators to compare Cell Source value to that of its competitors to determine the firm's financial worth. Cell Source is rated second in beta category among its peers. It is number one stock in ebitda category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cell Source's earnings, one of the primary drivers of an investment's value.Cell EBITDA vs. Beta
Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Cell Source |
| = | -64.41 |
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Cell Source |
| = | (4.11 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Cell EBITDA Comparison
Cell Source is currently under evaluation in ebitda category among its peers.
Beta Analysis
As returns on the market increase, returns on owning Cell Source are expected to decrease by larger amounts. On the other hand, during market turmoil, Cell Source is expected to outperform it.
Cell Source Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cell Source, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cell Source will eventually generate negative long term returns. The profitability progress is the general direction of Cell Source's change in net profit over the period of time. It can combine multiple indicators of Cell Source, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Cell Source, Inc., a biotechnology company, develops cell therapy treatments based on the management of immune tolerance. Cell Source, Inc. was founded in 2012 and is headquartered in New York, New York. Cell Source operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 1 people.
Cell Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cell Source. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cell Source position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cell Source's important profitability drivers and their relationship over time.
Use Cell Source in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cell Source position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cell Source will appreciate offsetting losses from the drop in the long position's value.Cell Source Pair Trading
Cell Source Pair Trading Analysis
The ability to find closely correlated positions to Cell Source could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cell Source when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cell Source - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cell Source to buy it.
The correlation of Cell Source is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cell Source moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cell Source moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cell Source can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cell Source position
In addition to having Cell Source in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Aggressive Funds Thematic Idea Now
Aggressive Funds
Funds or Etfs that attempt to achieve high capital gains by investing in companies with high growth potential and above average risk. The Aggressive Funds theme has 43 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Aggressive Funds Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Cell OTC Stock Analysis
When running Cell Source's price analysis, check to measure Cell Source's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cell Source is operating at the current time. Most of Cell Source's value examination focuses on studying past and present price action to predict the probability of Cell Source's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cell Source's price. Additionally, you may evaluate how the addition of Cell Source to your portfolios can decrease your overall portfolio volatility.